Follistatin vs IGF-1 LR3

What is actually being compared?

Human follistatin (FST) is an endogenous protein with multiple isoforms. The FST344 precursor gives rise to the mature FST315 protein; the two numbers do not describe interchangeable administered products. Follistatin binds activin-family ligands, including activin A and myostatin, but a binding mechanism is not itself a demonstrated treatment effect. UniProt human FST documents the sequence and processing, while the activin A–follistatin structure establishes one ligand-binding interaction.

IGF-1 LR3 (Long R3 IGF-I) is an engineered IGF-1 analogue with an N-terminal extension and a position-3 Glu-to-Arg substitution. An original analogue study documented lower binding-protein interaction and cell responses that depended on the model: LR3 was less potent than native IGF-1 in cells without detectable IGF-binding proteins. A separate human dermal fibroblast culture study reported receptor interaction with no detectable IGFBP-3 binding in its assay. These laboratory observations do not imply stronger receptor affinity, superior human efficacy, or established safety.

What the studies measured

In a six-person, open-label Becker muscular dystrophy AAV1-FS344 study, four participants had reported six-minute-walk gains and two did not improve. A separate sporadic inclusion-body myositis report involved six recipients of AAV1-FS344 plus exercise and eight matched untreated comparators, without random assignment. Its efficacy interpretation was publicly challenged. Both reports concern gene transfer in defined diseases, not direct follistatin protein or enhancement in healthy adults. A separate DMD AAV1-FS344 registry posted results for three participants: none had increased six-minute-walk distance and one had North Star Ambulatory Assessment improvement. This small single-group record does not establish effectiveness or safety.

ACE-083 is also a distinct intervention. A phase 1 study in 58 postmenopausal women reported greater local muscle volume but no mean strength improvement. A randomized phase 2 FSHD study likewise found volume changes without consistent functional improvement. These observations cannot be used as proof of native follistatin’s clinical effect.

IGF-1 LR3 has directly measured effects in animals, with results varying by species and context. A rat experiment found stronger growth-related responses than unmodified IGF-1 under its experimental conditions. In contrast, finisher pigs given LR3 had lower daily gain and food intake. In a more recent growth-restricted fetal-sheep study, one week of LR3 did not improve fetal weight compared with vehicle. None of these is a human muscle-benefit or long-term-safety trial.

Why a combination cannot be inferred

A mouse follistatin pathway study examined the role of IGF-1 receptor/Akt/mTOR signaling in follistatin-associated hypertrophy. It did not test an administered follistatin-plus-IGF-1-LR3 regimen. A follow-up animal study further separated IGF-I ligand from insulin-related effects. Neither paper establishes that combining the two named compounds is effective, compatible, or safe in people.

Evidence boundary

The current primary records allow a comparison of biological targets and experimental models. They do not support a head-to-head effectiveness ranking, a human muscle-growth claim for either named compound, or a prediction of combination safety. The limited gene-transfer studies and preclinical LR3 experiments leave dose-response, long-term outcomes, and safety of the proposed comparison in people unresolved.